Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 5/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30197470 | 0.87 | USP2 (0.41) | USP2SMN1; SMN2CCR2EPHX2GPR119 | |
| SCHEMBL20337474 | 0.87 | USP2 (0.41) | USP2SMN1; SMN2CCR2EPHX2GPR119 | |
| SCHEMBL30833164 | 0.87 | USP2 (0.41) | USP2SMN1; SMN2CCR2EPHX2GPR119 | |
| SCHEMBL18392380 | 0.87 | USP2 (0.41) | USP2SMN1; SMN2CCR2EPHX2GPR119 | |
| SCHEMBL18328440 | 0.87 | USP2 (0.41) | USP2SMN1; SMN2CCR2EPHX2GPR119 | |
| SCHEMBL22798885 | 0.84 | PTPN11 (0.30) | — | |
| SCHEMBL29715769 | 0.79 | USP2 (0.40) | USP2SMN1; SMN2CCR2EPHX2GPR119 | |
| SCHEMBL22241134 | 0.78 | NPC1 (0.38) | USP2SMN1; SMN2CCR2EPHX2GPR119 | |
| SCHEMBL19736069 | 0.77 | USP2 (0.43) | USP2SMN1; SMN2EPHX2GPR119RECQL | |
| SCHEMBL29715575 | 0.76 | USP2 (0.42) | USP2SMN1; SMN2EPHX2GPR119RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3753941-B1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO LTD (CN) | 2024-05-01 | — | — | EP | disclosed |
| CN-115448923-B | Pyrimidine-fused ring compound, preparation method and application thereof | 上海青煜医药科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11498930-B2 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof | Blueray Therapeutics (Shanghai) Co., Ltd (CN) | 2022-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498930-B2 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof | PTPN11, PPM1F, PTPRF | USP2 3618/4885SMN1; SMN2 3594/4885CCR2 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.